{"id":"NCT03338010","sponsor":"Eli Lilly and Company","briefTitle":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus","officialTitle":"A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-22","primaryCompletion":"2020-03-18","completion":"2020-03-18","firstPosted":"2017-11-09","resultsPosted":"2021-05-25","lastUpdate":"2021-05-25"},"enrollment":536,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"LY2963016","otherNames":[]},{"type":"DRUG","name":"Lantus®","otherNames":[]}],"arms":[{"label":"LY2963016","type":"EXPERIMENTAL"},{"label":"Lantus®","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications (OAMs). Participants will continue their OAMs throughout the study.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®)","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"LY2963016","deltaMin":-1.27,"sd":0.043},{"arm":"Lantus®","deltaMin":-1.23,"sd":0.062}],"pValues":[{"comp":"OG000 vs OG001","p":"0.545"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":32,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":359},"commonTop":["Upper respiratory tract infection","Hypertension","Weight increased","Injection site pain","Cough"]}}